Novartis’ Kisqali, combined with endocrine therapy, offered almost a year of progression-free survival (PFS) for an aggressive form of HER+/HER2- metastatic breast cancer, the company announced Tuesday.
https://www.pharmalive.com/wp-content/uploads/2022/12/BioSpaceNovartis12-7-2022.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-12-07 10:57:572022-12-07 10:57:57Novartis’ Kisqali hits mark in mid-stage breast cancer trial
